This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

The Deal: Suntory Seen Near $1.6B GSK Drinks Deal

Stocks in this article: GSK

LONDON ( The Deal) -- Suntory Holdings' recently listed Suntory Beverage & Food is widely reported to be close to buying the Ribena and Lucozade drinks brands put up for sale by the U.K.'s GlaxoSmithKline (GSK) in April.

The purchase, for an estimated 1 billion pounds ($1.6 billion), would mark a major push into Britain for the Japanese company, which became a significant force in Europe with its acquisition of France's Orangina from Blackstone Group (BX) and Lion Capital (LCHL) in 2009 for 300 billion yen ($3.01 billion).

In June, Suntory Beverage raised 388 billion yen in an initial public offering, with proceeds earmarked for a planned 500 billion yen acquisition drive as it seeks to double sales to 2 trillion yen by 2020 through overseas expansion.

The blackcurrant-flavored Ribena and Lucozade, a glaring-orange glucose drink, occupy a similar place in Britons' cultural consciousness to Orangina soda for the French. Lucozade, traditionally used as a pick-me-up during illness, has recently been chasing the sports and exercise drinks market. Pharma giant GlaxoSmithKline's April decision to sell the brands was a long time in the making. The British company at the same time also hived off around 50 older, or "tail," drugs brands with 2012 revenue of about 3 billion pounds into a separate unit which could be sold.

Beyond expanding Suntory's global empire and distribution reach, the deal should also reassure those who worry that the voracious appetite among Japanese companies for outbound acquisitions is diminishing because of the yen's retreat from historic highs. Yet Japan's banks have been active acquirers this year, particularly in Southeast Asia, and, only on Thursday, Otsuka Pharmaceutical agreed to pay $886 million for Dublin, Calif.-based Astex Pharmaceuticals.

Dealogic figures show that Japanese companies struck 416 outbound deals in the year to Sept. 6, down from 513 in the year-earlier period. The value of Japanese outbound acquisitions in the year to date was $27.8 billion, down from $56.8 billion in the corresponding 2012 period, when the year started with several big-ticket transactions. The value of outbound deals by Japanese banks in 2013 to date more than doubled year-on-year to $7.6 billion, Dealogic figures show. Separate figures from law firm Allen & Overy LLP found that Japan was the No. 6 outbound acquirer in the first half.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs